OKYO Pharma enrolls first patients in Phase 3 NEPTUNE trial for neuropathic corneal pain

OKYO Pharma enrolled the first patients in its Phase 3 NEPTUNE pivotal trial of urcosimod for neuropathic corneal pain. The study targets a chronic eye-pain condition with no FDA-approved therapies.